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ABSTRACT
Patients on long-term hemodialysis are at very high risk for cardiovascular disease but are usually excluded from clinical
trials conducted in the general population or in at-risk populations. There are no universally agreed cardiovascular
outcomes for trials conducted specifically in the hemodialysis population. In this review, we highlight that trials reporting
cardiovascular outcomes in hemodialysis patients are usually of short duration (median 3 to 6 months) and are small
(59% of trials have <100 participants). Overall, the cardiovascular outcomes are very heterogeneous and may not reflect
outcomes that are meaningful to patients and clinicians in supporting decision making, as they are often surrogates
of uncertain clinical importance. Composite outcomes used in different trials rarely share the same components. In a field
in which a single trial is often insufficiently powered to fully assess the clinical and economic impact of interventions,
differences in outcome reporting across trials make the task of meta-analysis and interpretation of all the available
evidence challenging. Core outcome sets are now being established across many specialties in health care to prevent
these problems. Through the global Standardized Outcomes in Nephrology–Hemodialysis initiative, cardiovascular
disease was identified as a critically important core domain to be reported in all trials in hemodialysis. Informed by
the current state of reporting of cardiovascular outcomes, a core outcome measure for cardiovascular disease is
currently being established with involvement of patients, caregivers, and health professionals. Consistent reporting
of cardiovascular outcomes that are critically important to hemodialysis patients and clinicians will strengthen
the evidence base to inform care in this very high-risk population. (J Am Coll Cardiol 2018;71:2802–10)
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“‘W hen I use a word,’ HumptyDumpty said, in rather a scornfultone, ‘it means just what I choose
it to mean—neither more nor less.’ ‘The question is,’
said Alice, ‘whether you can make words mean so
many different things.’” In writing Through the Look-
ing Glass, Lewis Carroll (1) could have been referring
to cardiovascular outcomes reported in clinical trials,
particularly among patients on hemodialysis.
CARDIOVASCULAR DISEASE
AND HEMODIALYSIS
Worldwide, >2 million people have end-stage kidney
disease, with this number increasing annually by 5%
to 7% (2). Patients with end-stage kidney disease who
are treated with dialysis require a disproportionately
high amount of health care resources. The prevalence
of cardiovascular disease (CVD) in people on hemo-
dialysis exceeds 60% (3,4) and accounts for >50% of
deaths (4–6). CVD mortality remains up to 30 times
higher in people on dialysis than in the general
population (6).
THE IMPORTANCE OF AN OUTCOME
Clinical trials of interventions designed to reduce
CVD in patients with end-stage kidney disease
have evaluated the use of medications (7–10) and the
intensity and type of hemodialysis (11–13), but
the results have generally not identified clear
evidence of benefit. Such trials may have been less
informative than possible because they were too
small to identify modest but realistic treatment
effects. Inconsistencies in how cardiovascular out-
comes were measured and reported made it difficult
to compare the effectiveness of interventions across
different trials or to combine trial results in meta-
analyses (14). Reporting bias, both in terms of selec-
tive outcome reporting and publication bias, also has
the potential to cause misinterpretation of evidence
(15). The value of trials to inform decision
making among patients, clinicians, and policy
makers may also be reduced if the outcomes
are selected on the basis of feasibility rather
than importance (16).
The importance of choosing the right out-
comes for clinical trials to inform decision making is
widely accepted, but appropriate measurement of
cardiovascular outcomes in trials can be challenging. In
particular, the major cardiovascular outcomes occur
only in a relatively small fraction of participants
meaning, unless trials are very large, follow-up periods
may need to be long in order to capture a sufficient
number of specific events. This has led to an increasing
use of composite outcomes to increase the number
of events captured and to reduce sample size
requirements (17,18). When using composite end-
points, it is difficult to estimate the true effect of an
intervention ondifferent components of the composite,
particularly those that occur less frequently. Compos-
ites often combine outcomes with very different levels
of importance to patients, making interpretation of the
overall importance of the trial findings difficult (18,19).
Similarly, a compounding problem is that inclusion of
surrogates diverts attention from outcomes of more
importance to patients and clinicians (20). Outcomes
need to be relevant to all stakeholders, in particular the
patients within the specific disease group (21).
The capacity to compare outcomes across trials
and produce summary effect estimates through
meta-analysis would help improve confidence in the
effects of interventions in the hemodialysis popula-
tion but would require that the outcomes be reported
consistently.
THE NEED FOR CORE OUTCOME SETS
A core outcome set is an agreed standardized set
of outcomes that should be measured and reported,
as a minimum, in all clinical trials in the relevant
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AB BR E V I A T I O N S
AND ACRONYM S
CVD = cardiovascular disease
MACE = major adverse cardiac
event(s)
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areas of health or health care (22). Recently, there
has been a proliferation of discipline-specific and
global initiatives to develop core outcome sets
(23,24). The Outcome Measures in Rheumatology
initiative was formed in 1992 and set the foundation
for the development of core outcomes, specifically
in rheumatology trials. With the involvement
of patients, health care providers, and policy
makers, Outcome Measures in Rheumatology has
improved the relevance of outcomes reported in
rheumatology trials. More recently, the Core Outcome
Measures in Effectiveness Trials initiative was
established to facilitate the development and
collation of core outcome sets across all diseases
internationally (23).
Among cardiovascular trialists, there have been
concerted efforts to standardize cardiovascular
outcome reporting (25–27). Early attempts include the
introduction of the term MACE, defined as “major
adverse cardiac event(s),” in the mid-1990s, with its
use theoretically restricted to in-hospital complica-
tions related to percutaneous coronary interventions
(28). However, the components of a MACE vary, even
among trials of similar interventions. For example, a
systematic review assessing the components of MACE
used in studies comparing bare-metal versus drug-
eluting stents found large-scale heterogeneity in the
outcomes used (29). The use of “MACE” has become
widespread, but the term is often used outside its
original context with a large number of varied outcome
measures used to make up the composite endpoint
(29). More recently, a number of core outcome sets
have been developed for CVDs in specific populations,
including a set for the effectiveness of cardiac surgery
(30) and a set for pregnant women with CVD (31).
CURRENT STATE OF REPORTING OF CVD
OUTCOMES IN HEMODIALYSIS TRIALS
A systematic search was conducted in MEDLINE,
Embase, the Cochrane Kidney and Transplant
Specialized Register, and ClinicalTrials.gov for ran-
domized controlled trials conducted in adults on
hemodialysis (both published or in progress, from
2011 to 2017), which reported at least 1 cardiovascular
outcome (Online Table 1). We extracted a number of
trial characteristics as well as all cardiovascular
outcome measures, including all levels of specifica-
tion (if reported), and the specific metric (e.g., time to
event, change from baseline), method of aggregation
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Citations identified in Embase, Cochrane
specialized register, MEDLINE
(January 2011 to August 2016)
N = 1,390
Comprehensive search of MEDLINE, Embase, the Cochrane Kidney and Transplant Specialized Register, and ClinicalTrials.gov from 2011 to
2017 resulted in 174 randomized trials in patients on hemodialysis (HD) reporting at least 1 cardiovascular outcome. CVD ¼ cardiovascular
disease.
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(e.g., mean, median, proportion), and time point of
measurement (32).
We classified the outcomes into 236 measures (e.g.,
troponin) and then again into 26 outcome groups
(e.g., cardiac biomarker). A schema of the categori-
zation is provided in Online Figure 1, with an example
in Online Table 2. Outcomes were further classified as
surrogate, clinical, or patient reported. A surrogate
outcome was defined as a biochemical, imaging, or
other marker used as a substitute for a clinical
outcome (33). A clinical outcome was defined as a
medical event or comorbidity (e.g., mortality,
myocardial infarction, hospitalization) diagnosed by
the clinician. Patient-reported outcomes were those
reported directly by patients regarding how they
function or feel in relation to a health condition and
its therapy, without interpretation by a health care
professional or anyone else (34).
TRIAL CHARACTERISTICS. We identified and included
174 trials involving 148,730 participants (Figure 1).
Trial characteristics are presented in Table 1. Fifty-six
trials (32%) were unpublished. The published trials
were conducted across 28 countries, most frequently
in Japan (8%) and the United States (8%), and 12 trials
(7%) were multinational. The median trial duration
was 15.0 months (interquartile range: 5.5 to
42.0 months), and the median sample size was 83
participants (interquartile range: 32 to 200 partici-
pants). It is of note that relative to many cardiovas-
cular trials in the general population, both the trial
duration and the sample size are small. The most
common type of intervention was pharmacological
(103 trials [60%]). In 48 trials (27%), the intervention
was a dialysate, dialysis membrane, or modality
of hemodialysis (such as hemodiafiltration or
hemodialysis).
OUTCOMES AND OUTCOME MEASURES. The 1,743
definitions (including different time points of
measurement) were categorized into 236 measures
(e.g., troponin), with a median of 3.5 outcome mea-
sures reported per trial (range: 1 to 23). Across all
trials, measures were assessed at 67 different time
points with a range of 1 to 6 time points per trial.
The number of measures was not associated with the
sample size (Online Table 3). These measures were
further grouped into 26 outcomes (e.g., cardiac
biomarkers), with a median of 2 outcomes reported
per trial (range: 1 to 16). Of the 26 outcomes, 15 (58%)
were clinical, 10 (38%) were surrogates, and 1 (4%)
was a patient-reported outcome: pain (Central
Illustration). The top 3 most frequently reported
outcomes were serum biomarkers (excluding lipids
and traditional cardiac biomarkers; 52 trials [30%]),
cardiovascular composite (52 trials [30%]), and serum
lipid levels (41 trials [23%]).
The number of measures for each outcome ranged
from 1 to 61 (Figure 2). The serum biomarker outcome
included 61 different biomarker measures; C-reactive
protein was the most frequently reported biomarker
(34 trials [20%]), followed by homocysteine (8 trials
[5%]). The outcome cardiovascular composite
included 11 composite measures, the 3 most frequent
being a “cardiovascular composite” measure (e.g.,
“the cumulative rate of non-fatal MI [myocardial
infarction] or acute coronary syndrome, hospitaliza-
tion for heart failure, nonfatal stroke or CV [cardio-
vascular] death”; 27 trials [16%]), a “cardiovascular
event” (e.g., “rate of cardiovascular events”;
TABLE 1 Characteristics of Included Trials (n ¼ 174)













Not published 56 32
Region/country
Not stated 64 37
Europe 43 25
Asia 23 13
United States 13 7
International 12 7
Middle East 11 6
South/Central America 4 2
Australasia 4 2











Mode of hemodialysis 26 15
Lifestyle 6 3
Other 5 3
Dialysis machine 9 5
Coronary intervention 3 2
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CENTRAL ILLUSTRATION Cardiovascular Outcomes in Hemodialysis: Proportion of Trials
Reporting Each Outcome (174 Trials, 26 Outcomes)
O’Lone, E. et al. J Am Coll Cardiol. 2018;71(24):2802–10.
Chart to show the 26 outcome groups determined from the 174 trials and the proportion of trials that reported them. The most frequently
reported outcomes were the surrogate outcome of serum biomarker and a cardiovascular composite outcome. Only 1 outcome was patient
reported. ACS ¼ acute coronary syndrome; ECG ¼ electrocardiography.
O’Lone et al. J A C C V O L . 7 1 , N O . 2 4 , 2 0 1 8
CV Outcomes in Hemodialysis Trials J U N E 1 9 , 2 0 1 8 : 2 8 0 2 – 1 0
2806
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on January 22, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
24 [14%] trials), and “cardiovascular event non-fatal”
(4 trials [2%]) (Figure 2). The outcome serum lipid
levels had 10 different measures, the 3 most
frequently reported being high-density lipoprotein
(26 trials [15%]), triglycerides (26 [15%] trials), and
“total cholesterol” (21 [12%] trials).
Across the clinical outcomes, 13 different metrics
were used to report the original definitions, including
number of events, rate of event, event free survival,
and time to event. The methods of aggregation
for the clinical outcomes included mean, median,
proportion, and proportional change.
CARDIOVASCULAR COMPOSITE OUTCOME. Each
composite measure was deconstructed into its
components, and the number of trials using
each component was analyzed as shown in Figure 3.
Fifty-one trials (29%) used cardiovascular composite
measures, and each trial used a range of 1 to 6
different composite combinations. Within these
51 trials, there were 50 unique composite combina-
tions (Figure 3). The proportion of trials reporting
each measure within the cardiovascular composite
outcome is shown in Online Figure 2.
MORTALITY OUTCOMES. Cardiovascular mortality
outcomes were reported in 25 (14%) trials. Included in
the mortality outcome were 8 individual events, of
which sudden cardiac death was the most frequently
reported (7 trials [4%]) (Online Figure 3). Composite
mortality measures were assessed in 14 trials (8%),
and 12 composite combinations were used (Figure 4).
Within the mortality outcome, the most frequently
reported composite outcome measure was cardio-
vascular death, reported as a unique term in 16 trials
(9%) and also used in 5 mortality composite combi-
nations (42%) (Figure 4).
TIME FOR MORE CONFIDENCE IN OUTCOMES
In contemporary clinical trials conducted in patients
on hemodialysis, a very large number of different
cardiovascular outcomes have been reported. Over a
third of these outcomes were classified as surrogates
rather than outcomes that would be expected to be
directly important to patients and clinicians (such as
sudden cardiac death, myocardial infarction), and
only 1 was patient reported (pain). The use of






























































































































































































Bar chart showing how the number of different measures contributed to each outcome excluding time points. There were 61 different
biomarkers measured in the outcome group other serum biomarkers and 32 different ways of measuring vascular function and anatomy.
ACS ¼ acute coronary syndrome; CV ¼ cardiovascular; ECG ¼ electrocardiography; MI ¼ myocardial infarction; PVD ¼ peripheral vascular
disease.
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surrogate outcomes is probably a function of the
small sample sizes of most of the trials identified. Use
of composite outcomes was common, being used in a
third of the trials, but each trial used different com-
ponents to make up its composites, and they were
often ill defined, making comparisons across studies
problematic. This echoes the findings in other pop-
ulations regarding the complexity and discord within
composite outcomes (18,29). A review of composite
outcomes within cardiovascular trials found that the
components of composite endpoints varied widely in
terms of their importance to patients and in the
magnitude of their effect of the intervention. This can
give rise to misleading interpretations regarding the
impact of treatment (18).
The variety of measures used to assess each
outcome was substantial, particularly among the
surrogate outcomes, with more than 60 different
serum biomarkers measured and more than 30
different ways to measure vascular function and
anatomy. Heterogeneity was evident at multiple
levels, including definition of the measurement, the
metric, the method of aggregation, and the time point
of measurement of the outcome measure. This het-
erogeneity is not unique to the hemodialysis popu-
lation. In a review of outcomes in cardiac arrest trials,
more than 160 individual outcomes were reported,
including 39 different measures of survival (35).
This review highlights the urgent need to develop a
core outcome set in hemodialysis trials. Recently, the
Standardized Outcomes in Nephrology initiative was
established, which has used validated consensus
methodology to bring together patients and health
care professionals to identify critically important
outcomes in hemodialysis (36–38). CVD was identified
as a core outcome domain (along with vascular
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Cardiovascular Cardiac Thrombosis Heart failure MI, ACS, Angina
Individual components of composites
Stroke & TIA Arrest/SCD Revasc Other
Composites not further defined
Event
US US USNF NC Fatal throm unstab NF NFEvent Eventfatal hosp
Event Event US US Ang ACS CHD Coron MI MI MI MI TIA CVA Death Hem Hosp NF US CA
fatal NF resus <+ tension VF vasc cardiac event
event event
CA CA SCD CABG Cereb Coron US Hyper Hypo Hosp Periph AS AS Trials using
composite
(n)
DVT PE NFVA EmboSAE MorbDeath Death Death DeathDx
all
cause
Matrix to display the individual components of the 51 composite outcomes after deconstruction. The far right column tallies the number of trials that used each
composite, and the bottom row tallies the number of times each component was incorporated into a composite. Myocardial infarction was the most frequently used
component in a composite, and most composite combinations were only used in 1 or 2 trials. ACS ¼ acute coronary syndrome; Ang ¼ angina; AS ¼ atherosclerotic;
CA ¼ cardiac arrest; Cereb ¼ cerebrovascular; CHD ¼ coronary heart disease; Coron ¼ coronary; CVA ¼ cerebrovascular accident; DVT ¼ deep vein thrombosis;
Dx ¼ disease; Embol ¼ embolism; Hem ¼ hemorrhagic; Hosp ¼ hospitalization; MACE ¼ major adverse cardiovascular event; MI ¼ myocardial infarction;
Morb ¼ morbidity; NC ¼ noncoronary; NF ¼ nonfatal; PE ¼ pulmonary embolism; Periph ¼ peripheral; resus ¼ resuscitation; Revasc ¼ revascularization; SAE ¼ serious
adverse event; throm ¼ thrombosis; TIA ¼ transient ischemic attack; US ¼ unspecified; VA ¼ vascular access; vasc ¼ vascular; VF ¼ cardiac arrhythmia.
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access, fatigue, and mortality). The next phase of the
Standardized Outcomes in Nephrology initiative aims
to establish these core measures with consensus on
their definition. Moving forward, this effort will
facilitate improvement in the quality, transparency,
and value of cardiovascular trials in people on he-
modialysis and, most important, has the potential to
improve interpretation of clinical trials data in the
hope of reducing mortality and morbidity for people
on hemodialysis.
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